Construction of safe and effective live tuberculosis vaccines

安全有效的结核活疫苗的构建

基本信息

  • 批准号:
    8083413
  • 负责人:
  • 金额:
    $ 41.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-03-01 至 2016-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal seeks to understand in greater detail the mechanisms by which Mycobacterium tuberculosis blocks the priming of effective host immunity, with the ultimate goal of using this information to create more effective live vaccine strains. Previous work identified multiple mycobacterial genes involved in blocking apoptosis of infected host cells, which is intimately linked to the ability of the pathogen to prevent presentation of its antigens by MHC class I. Extensive preliminary work has also identified genes in M. tuberculosis that interfere with MHC class II antigen presentation, and genes that block production of key cytokines. A major goal of this proposal is to construct safely attenuated strains of M. tuberculosis in which specific immune evasion genes have been deleted, thus creating more effective vaccines for priming of anti- mycobacterial immunity. The approach involves identifying the most potent anti- apoptotic genes from a group of four candidates that have already been partially characterized, and combining mutations in these with strongly attenuating auxotrophy mutations to eliminate virulence. Precise mutations in the genes of interest will be created using allelic exchange mediated by specialized transducing phages, a methodology that is well established in the laboratory of the PI and his collaborators. The potency of candidate vaccine strains will be further enhanced by incorporating additional mutations in genes that interfere with MHC class II presentation, or with production of IL-12p70 or TNF. Immunological studies of CD4 and CD8 T cell priming by candidate vaccine strains will be carried out in mouse models, allowing identification of the most favorable combinations of specific gene deletions to advance into preclinical vaccination studies in rodents. Studies of the induction of stable T cell memory by candidate vaccine strains will be performed in mice, and the impact of boosting primary responses with mycobacterial proteins will also be initiated. Overall, the proposed studies will significantly advance our understanding of the host-pathogen interaction in tuberculosis, and contribute directly to vaccine development for prevention and control of this major human disease. PUBLIC HEALTH RELEVANCE: This proposal aims to understand in greater detail the mechanisms by which Mycobacterium tuberculosis evades host immunity to cause serious disease and mortality. The information gained will be applied to the design and construction of better vaccines for the prevention of tuberculosis.
描述(由申请方提供):本提案旨在更详细地了解结核分枝杆菌阻断有效宿主免疫启动的机制,最终目标是利用该信息创建更有效的活疫苗株。先前的工作确定了参与阻断受感染宿主细胞凋亡的多个分枝杆菌基因,这与病原体阻止MHC I类呈递其抗原的能力密切相关。广泛的前期工作也确定了M.干扰MHC II类抗原呈递的结核病基因,以及阻断关键细胞因子产生的基因。本研究的主要目的是构建安全的M.结核病,其中特定的免疫逃避基因已被删除,从而创造了更有效的疫苗,用于引发抗分枝杆菌免疫。该方法涉及从一组已经部分表征的四个候选基因中鉴定最有效的抗凋亡基因,并将这些基因中的突变与强烈减毒的营养缺陷型突变相结合以消除毒力。将使用由专门的转导酶介导的等位基因交换来创建感兴趣基因中的精确突变,这是PI及其合作者的实验室中充分建立的方法。候选疫苗株的效力将通过在干扰MHC II类呈递或干扰IL-12 p70或TNF产生的基因中掺入额外的突变来进一步增强。将在小鼠模型中进行候选疫苗株对CD 4和CD 8 T细胞引发的免疫学研究,以确定特定基因缺失的最有利组合,从而推进啮齿动物的临床前疫苗接种研究。将在小鼠中进行候选疫苗株诱导稳定T细胞记忆的研究,还将启动用分枝杆菌蛋白加强初级应答的影响。总的来说,拟议的研究将大大提高我们对结核病中宿主-病原体相互作用的理解,并直接有助于预防和控制这一重大人类疾病的疫苗开发。 公共卫生关系:该提案旨在更详细地了解结核分枝杆菌逃避宿主免疫而导致严重疾病和死亡的机制。所获得的信息将用于设计和制造更好的预防结核病的疫苗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven A Porcelli其他文献

Steven A Porcelli的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven A Porcelli', 18)}}的其他基金

Flow Cytometery and Cell Sorting Core
流式细胞仪和细胞分选核心
  • 批准号:
    10659181
  • 财政年份:
    2022
  • 资助金额:
    $ 41.5万
  • 项目类别:
Flow Cytometery and Cell Sorting Core
流式细胞仪和细胞分选核心
  • 批准号:
    10408970
  • 财政年份:
    2022
  • 资助金额:
    $ 41.5万
  • 项目类别:
Bigfoot Multispectral High Speed Fluorescence Activated Cell Sorter
Bigfoot 多光谱高速荧光激活细胞分选仪
  • 批准号:
    10414835
  • 财政年份:
    2022
  • 资助金额:
    $ 41.5万
  • 项目类别:
"Determinants of T Cell Immunity to Tuberculosis Vaccines"
“T细胞对结核疫苗免疫的决定因素”
  • 批准号:
    8871648
  • 财政年份:
    2015
  • 资助金额:
    $ 41.5万
  • 项目类别:
Flow Cytometry Core
流式细胞术核心
  • 批准号:
    8871652
  • 财政年份:
    2015
  • 资助金额:
    $ 41.5万
  • 项目类别:
Construction of safe and effective live tuberculosis vaccines
安全有效的结核活疫苗的构建
  • 批准号:
    8230473
  • 财政年份:
    2011
  • 资助金额:
    $ 41.5万
  • 项目类别:
Defining the Correlates of Bactericidal Immunity in Tuberculosis
定义结核病杀菌免疫的相关性
  • 批准号:
    8031491
  • 财政年份:
    2011
  • 资助金额:
    $ 41.5万
  • 项目类别:
Construction of safe and effective live tuberculosis vaccines
安全有效的结核活疫苗的构建
  • 批准号:
    8626351
  • 财政年份:
    2011
  • 资助金额:
    $ 41.5万
  • 项目类别:
"Determinants of T Cell Immunity to Tuberculosis Vaccines"
“T细胞对结核疫苗免疫的决定因素”
  • 批准号:
    8049854
  • 财政年份:
    2011
  • 资助金额:
    $ 41.5万
  • 项目类别:
Flow Cytometry Core
流式细胞术核心
  • 批准号:
    8049861
  • 财政年份:
    2011
  • 资助金额:
    $ 41.5万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 41.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 41.5万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 41.5万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 41.5万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 41.5万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 41.5万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 41.5万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 41.5万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 41.5万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 41.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了